NasdaqCM - Nasdaq Real Time Price USD

Jade Biosciences, Inc. (JBIO)

7.72

+0.30

+(3.98%)

At close: May 20 at 4:00:01 PM EDT

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Completed reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027 Lead candidate JADE101 expected to enter the clinic in second half of 2025, with interim biomarker-rich data expected in first half of 2026 SAN FRANCISCO and VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies

GlobeNewswire 6 days ago

JBIO
+3.98%
Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

SAN FRANCISCO and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the Jefferies Global Healthcare Conference, June 3-5, 2025, in New York. Tom Frohlich, Chief Executive Officer of Jade, will deliver a company presentation on Wednesday, June 4 at 4:55-5:25 p.m. ET. Members of the management team will also

GlobeNewswire 7 days ago

JBIO
+3.98%

Performance Overview

Return	JBIO	S&P 500 (^GSPC)
YTD	-91.46%	+1.00%
1-Year	-98.88%	+11.91%
3-Year	-98.28%	+52.27%